



*NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO  
OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA*

**OCTOPLUS LAUNCHES EQUITY OFFERING WITH AIMED PROCEEDS  
OF €4 MILLION**

**Leiden, the Netherlands, 25 October 2011** – OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), announces today that it launches an offering of ordinary shares with an aim of raising gross proceeds of €4 million (the “Offering”).

The Offering shall be structured as a private placement. The offer price of the ordinary shares offered is €0.50 per share (the “Offer Price”).

Petercam will act as sole lead manager and placement agent in relation to the Offering. The Offering shall be launched immediately following the release of this announcement and is expected to close on Wednesday 26 October 2011. Settlement of the Offering is expected to take place on Monday 31 October 2011.

With regard to the Offering:

- OctoPlus swaps an amount of new shares that is equal to the number of shares offered in the Offering with three major shareholders in exchange for an equal number of existing ordinary shares of OctoPlus currently held by these shareholders.
- The existing ordinary shares, which are delivered to OctoPlus, will be placed by OctoPlus in a non-pre-emptive placement with qualified investors in the Netherlands and elsewhere in the framework of the Offering.
- A number of the Company’s existing shareholders, including the Company’s CEO, Mr. Jan Hendrik Egberts, and certain new investors have committed themselves to subscribe for shares in the Offering for a substantial part of the amount that OctoPlus aims to raise, subject to €4 million in gross proceeds being raised.
- The new ordinary shares will rank *pari passu* in all respects with OctoPlus’ existing issued ordinary shares and in order to ensure that the new ordinary shares are marketable on the stock exchange of NYSE Euronext in Amsterdam OctoPlus will procure to have the new ordinary shares listed and admitted to trading on NYSE Euronext in Amsterdam on or before the date that is 90 days after the settlement of the Offering on the basis of a prospectus to be prepared by OctoPlus and be approved by the Dutch Authority for the Financial Markets (AFM) and in accordance with the rules and regulations of NYSE Euronext in Amsterdam.

---

**Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to U.S. persons. This announcement is not a prospectus and does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction.**

**The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from, or to or for the account of U.S. persons (as such term is defined in Regulation S under the Securities Act) or transaction not subject to, the registration requirements of the Securities Act.**

**In connection with the admission of the shares in the capital of the Company to trading on NYSE Euronext in Amsterdam, a prospectus will be made generally available in due course. Copies of the Prospectus will be available at no cost through the website of Euronext Amsterdam (Dutch residents only) and the website of the Company.**

OctoPlus intends to use the proceeds of the private placement for working capital purposes and to retain upside by co-investing along with clients in selected high-value projects in the area of specialty generics.

Jan Egberts, CEO of OctoPlus, says: *"We see promising opportunities in the specialty generics area. A number of long-acting injectables are coming off patent in the next few years, enabling us to develop a generic version of those formulations. The required development process is complex and specialised and fits well with our expertise in difficult to formulate injectables. We are well positioned to develop such products. The proceeds of this transaction will allow us to increase our participation in the long-term financial upside of these specialty generics."*

### **Contact**

For further information about OctoPlus and the Offering, please contact Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071 or send an e-mail to Investor Relations at [IR@octoplus.nl](mailto:IR@octoplus.nl).

### **About OctoPlus**

OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on our proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus also focuses on the development of long-acting, controlled release versions of known protein therapeutics, peptides and small molecules, including specialty generics.

The clinically most advanced product incorporating our technology is Locteron<sup>®</sup>, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and has recently completed Phase IIb clinical studies with superior clinical data versus current treatment.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on NYSE Euronext in Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website [www.octoplus.nl](http://www.octoplus.nl).

*This announcement is not an offer to sell or a solicitation of any offer to buy the securities of OctoPlus (the "Securities") in the United States or in any other jurisdiction.*

*The shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to or for the account or benefit of, U.S. persons (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or an exemption from such registration is available. No public offering of Securities of OctoPlus is being made in the United States.*

---

**Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to U.S. persons. This announcement is not a prospectus and does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction.**

**The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from, or to or for the account of U.S. persons (as such term is defined in Regulation S under the Securities Act) or transaction not subject to, the registration requirements of the Securities Act.**

**In connection with the admission of the shares in the capital of the Company to trading on NYSE Euronext in Amsterdam, a prospectus will be made generally available in due course. Copies of the Prospectus will be available at no cost through the website of Euronext Amsterdam (Dutch residents only) and the website of the Company.**

*This announcement does not constitute a prospectus. When made generally available, copies of the prospectus may be obtained at no cost through the website of Euronext Amsterdam (Dutch residents only) and the website of OctoPlus.*

*This document may contain certain forward-looking statements relating to the business, financial performance and results of the Company and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.*

---

**Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to U.S. persons. This announcement is not a prospectus and does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction.**

**The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from, or to or for the account of U.S. persons (as such term is defined in Regulation S under the Securities Act) or transaction not subject to, the registration requirements of the Securities Act.**

**In connection with the admission of the shares in the capital of the Company to trading on NYSE Euronext in Amsterdam, a prospectus will be made generally available in due course. Copies of the Prospectus will be available at no cost through the website of Euronext Amsterdam (Dutch residents only) and the website of the Company.**